The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017–2019

Background: In Poland, breast cancer (BC) is the most frequently diagnosed cancer in women and the second most common cause of death after lung cancer. This disease has important economic implications for patients, public payers, and the whole Polish economy. This study aimed to estimate the total N...

Descripción completa

Detalles Bibliográficos
Autores principales: Seweryn, Michal, Banas, Tomasz, Augustynska, Joanna, Lorenc, Ola, Kopel, Justyna, Pluta, Elzbieta, Skora, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778099/
https://www.ncbi.nlm.nih.gov/pubmed/36554267
http://dx.doi.org/10.3390/ijerph192416384
_version_ 1784856273448075264
author Seweryn, Michal
Banas, Tomasz
Augustynska, Joanna
Lorenc, Ola
Kopel, Justyna
Pluta, Elzbieta
Skora, Tomasz
author_facet Seweryn, Michal
Banas, Tomasz
Augustynska, Joanna
Lorenc, Ola
Kopel, Justyna
Pluta, Elzbieta
Skora, Tomasz
author_sort Seweryn, Michal
collection PubMed
description Background: In Poland, breast cancer (BC) is the most frequently diagnosed cancer in women and the second most common cause of death after lung cancer. This disease has important economic implications for patients, public payers, and the whole Polish economy. This study aimed to estimate the total National Health Fund (NHF) expenditures on the diagnosis and treatment of patients with breast cancer. In addition, the costs of productivity losses were also calculated. Methods: Cost estimation was prepared using a top-down approach. Direct cost calculations were based on data reported by NHF for patients with the diagnosis of breast cancer. Medical care costs included the following components: screening program, oncological package, surgical treatment, hospitalization, drug program, chemotherapy, radiotherapy, and outpatient care. Indirect costs in the form of absenteeism costs were calculated based on data from Statistics Poland (gross domestic product, number of employees) and the Social Insurance Institution database (the number of sick leave days). Results: Total expenditures for BC including direct costs and indirect costs amounted to EUR 305,371, EUR 332,998, and EUR 344,649, respectively in 2017, 2018, and 2019. Total healthcare costs in 2019 were EUR 4114 lower than in 2018, which resulted from the reduction in expenditure on the drug program (decrease of EUR 13,527), despite the observed increase in all remaining resources. From direct costs, the highest expense was spent on the drug program (nearly 50% of total direct costs), but this expense dropped significantly in 2019. For the remaining parameters, the costs increased year by year, of which the most expensive were surgical treatment (15%), radiotherapy (12%), and the screening program (10%). BC generated over EUR 120 thousand of social costs in 2019 and compared to 2017, there was an increase in productivity loss by 26%. Conclusions: Our results from 2017–2019 demonstrated that total expenditure for BC in Poland increased from year to year. Breast cancer generated almost EUR 345 thousand expenses in 2019, which translates into a significant burden on the public payer’s budget and the society in Poland.
format Online
Article
Text
id pubmed-9778099
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97780992022-12-23 The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017–2019 Seweryn, Michal Banas, Tomasz Augustynska, Joanna Lorenc, Ola Kopel, Justyna Pluta, Elzbieta Skora, Tomasz Int J Environ Res Public Health Article Background: In Poland, breast cancer (BC) is the most frequently diagnosed cancer in women and the second most common cause of death after lung cancer. This disease has important economic implications for patients, public payers, and the whole Polish economy. This study aimed to estimate the total National Health Fund (NHF) expenditures on the diagnosis and treatment of patients with breast cancer. In addition, the costs of productivity losses were also calculated. Methods: Cost estimation was prepared using a top-down approach. Direct cost calculations were based on data reported by NHF for patients with the diagnosis of breast cancer. Medical care costs included the following components: screening program, oncological package, surgical treatment, hospitalization, drug program, chemotherapy, radiotherapy, and outpatient care. Indirect costs in the form of absenteeism costs were calculated based on data from Statistics Poland (gross domestic product, number of employees) and the Social Insurance Institution database (the number of sick leave days). Results: Total expenditures for BC including direct costs and indirect costs amounted to EUR 305,371, EUR 332,998, and EUR 344,649, respectively in 2017, 2018, and 2019. Total healthcare costs in 2019 were EUR 4114 lower than in 2018, which resulted from the reduction in expenditure on the drug program (decrease of EUR 13,527), despite the observed increase in all remaining resources. From direct costs, the highest expense was spent on the drug program (nearly 50% of total direct costs), but this expense dropped significantly in 2019. For the remaining parameters, the costs increased year by year, of which the most expensive were surgical treatment (15%), radiotherapy (12%), and the screening program (10%). BC generated over EUR 120 thousand of social costs in 2019 and compared to 2017, there was an increase in productivity loss by 26%. Conclusions: Our results from 2017–2019 demonstrated that total expenditure for BC in Poland increased from year to year. Breast cancer generated almost EUR 345 thousand expenses in 2019, which translates into a significant burden on the public payer’s budget and the society in Poland. MDPI 2022-12-07 /pmc/articles/PMC9778099/ /pubmed/36554267 http://dx.doi.org/10.3390/ijerph192416384 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Seweryn, Michal
Banas, Tomasz
Augustynska, Joanna
Lorenc, Ola
Kopel, Justyna
Pluta, Elzbieta
Skora, Tomasz
The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017–2019
title The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017–2019
title_full The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017–2019
title_fullStr The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017–2019
title_full_unstemmed The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017–2019
title_short The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017–2019
title_sort direct and indirect costs of breast cancer in poland: estimates for 2017–2019
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778099/
https://www.ncbi.nlm.nih.gov/pubmed/36554267
http://dx.doi.org/10.3390/ijerph192416384
work_keys_str_mv AT sewerynmichal thedirectandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT banastomasz thedirectandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT augustynskajoanna thedirectandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT lorencola thedirectandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT kopeljustyna thedirectandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT plutaelzbieta thedirectandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT skoratomasz thedirectandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT sewerynmichal directandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT banastomasz directandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT augustynskajoanna directandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT lorencola directandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT kopeljustyna directandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT plutaelzbieta directandindirectcostsofbreastcancerinpolandestimatesfor20172019
AT skoratomasz directandindirectcostsofbreastcancerinpolandestimatesfor20172019